Literature DB >> 23737174

Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension.

Tamara Tajsic1, Nicholas W Morrell.   

Abstract

Pulmonary hypertension is a multifactorial disease characterized by sustained elevation of pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP). Central to the pathobiology of this disease is the process of vascular remodelling. This process involves structural and functional changes to the normal architecture of the walls of pulmonary arteries (PAs) that lead to increased muscularization of the muscular PAs, muscularization of the peripheral, previously nonmuscular, arteries of the respiratory acinus, formation of neointima, and formation of plexiform lesions. Underlying or contributing to the development of these lesions is hypertrophy, proliferation, migration, and resistance to apoptosis of medial cells and this article is concerned with the cellular and molecular mechanisms of these processes. In the first part of the article we focus on the concept of smooth muscle cell phenotype and the difficulties surrounding the identification and characterization of the cell/cells involved in the remodelling of the vessel media and we review the general mechanisms of cell hypertrophy, proliferation, migration and apoptosis. Then, in the larger part of the article, we review the factors identified thus far to be involved in PH intiation and/or progression and review and discuss their effects on pulmonary artery smooth muscle cells (PASMCs) the predominant cells in the tunica media of PAs.
© 2011 American Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23737174     DOI: 10.1002/cphy.c100026

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  44 in total

1.  Modulating the dysregulated migration of pulmonary arterial hypertensive smooth muscle cells with motif mimicking cell permeable peptides.

Authors:  Jamie L Wilson; Chamila Rupasinghe; Anny Usheva; Rod Warburton; Chloe Kaplan; Linda Taylor; Nicholas Hill; Dale F Mierke; Peter Polgar
Journal:  Curr Top Pept Protein Res       Date:  2015

Review 2.  Unique aspects of the developing lung circulation: structural development and regulation of vasomotor tone.

Authors:  Yuangsheng Gao; David N Cornfield; Kurt R Stenmark; Bernard Thébaud; Steven H Abman; J Usha Raj
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

3.  Protective effects of astragaloside IV against hypoxic pulmonary hypertension.

Authors:  Xiaozheng Zhang; Jun Chen; Pan Xu; Xin Tian
Journal:  Medchemcomm       Date:  2018-09-04       Impact factor: 3.597

4.  Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension.

Authors:  Kang Wu; Haiyang Tang; Ruizhu Lin; Shane G Carr; Ziyi Wang; Aleksandra Babicheva; Ramon J Ayon; Pritesh P Jain; Mingmei Xiong; Marisela Rodriguez; Shamin Rahimi; Francesca Balistrieri; Shayan Rahimi; Daniela Valdez-Jasso; Tatum S Simonson; Ankit A Desai; Joe G N Garcia; John Y-J Shyy; Patricia A Thistlethwaite; Jian Wang; Ayako Makino; Jason X-J Yuan
Journal:  Pulm Circ       Date:  2020-09-10       Impact factor: 3.017

5.  Transgenic expression of human matrix metalloproteinase-1 attenuates pulmonary arterial hypertension in mice.

Authors:  Joseph George; Jie Sun; Jeanine D'Armiento
Journal:  Clin Sci (Lond)       Date:  2012-01       Impact factor: 6.124

6.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

7.  BDNF secretion by human pulmonary artery endothelial cells in response to hypoxia.

Authors:  Martin Helan; Bharathi Aravamudan; William R Hartman; Michael A Thompson; Bruce D Johnson; Christina M Pabelick; Y S Prakash
Journal:  J Mol Cell Cardiol       Date:  2014-01-23       Impact factor: 5.000

8.  Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.

Authors:  Salil Sharma; Soban Umar; Francois Potus; Andrea Iorga; Gabriel Wong; David Meriwether; Sandra Breuils-Bonnet; Denise Mai; Kaveh Navab; David Ross; Mohamad Navab; Steeve Provencher; Alan M Fogelman; Sébastien Bonnet; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Circulation       Date:  2014-06-24       Impact factor: 29.690

9.  Versican accumulates in vascular lesions in pulmonary arterial hypertension.

Authors:  Ya-Ting Chang; Christina K Chan; Inger Eriksson; Pamela Y Johnson; Xiaofang Cao; Christian Westöö; Christian Norvik; Annika Andersson-Sjöland; Gunilla Westergren-Thorsson; Staffan Johansson; Ulf Hedin; Lena Kjellén; Thomas N Wight; Karin Tran-Lundmark
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

10.  Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy.

Authors:  Wei Feng; Jian Wang; Xin Yan; Cui Zhai; Wenhua Shi; Qingting Wang; Qianqian Zhang; Manxiang Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.